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BASIC BIOLOGY AND CLINICAL APPLICATION OF SPECIFIC
CYCLOOXYGENASE-2 INHIBITORS
LESLIE J. CROFFORD, PETER E. LIPSKY, PETER BROOKS, STEVEN B. ABRAMSON,
LEE S. SIMON, and LEO B. A. VAN DE PUTTE
The year 1999 marked the 100th anniversary of
the development of aspirin as a pharmaceutical com-
pound used for the treatment of rheumatic diseases. On
this anniversary, new drugs developed as a result of
advances in the understanding of prostanoid biosyn-
thetic pathways have become available for clinical use.
These drugs were specifically designed to inhibit the
cyclooxygenase (COX) activity of the inducible isoform
of prostaglandin H (PGH) synthase, or COX-2. The
rationale for the intensive drug development effort was
the hypothesis that specific inhibition of COX-2 would
have equal efficacy to, but significantly fewer gastroin-
testinal (GI) side effects than the nonsteroidal antiin-
flammatory drugs (NSAIDs) that nonspecifically inhibit
the COX enzymes. Understanding of COX-2 biology
provides a rationale for the use of specific COX-2
inhibitors in patients with rheumatic diseases, as well as
cautions related to the physiologic functions of COX-2.
Data from clinical trials provide support for the COX-2
hypothesis, though data collected after widespread use
of the specific COX-2 inhibitors will be needed in order
for a full understanding of these new compounds to be
achieved.
Background
The antiinflammatory, analgesic, and antipyretic
actions of aspirin became well known during the years
after its introduction. More recently, the beneficial
effects of the antithrombotic actions of aspirin in ath-
erosclerotic disease have been recognized (1). There is
strong epidemiologic evidence in support of a role for
aspirin as a chemopreventative agent for colon cancer
(2). In addition, there is evidence that the progression of
Alzheimer’s disease may be diminished by aspirin in-
gestion (2).
The NSAIDs, a group of chemically diverse com-
pounds that share the main therapeutic benefits of
aspirin, have also been found to share the most typical
side effects of aspirin, i.e., gastric upset, ulceration, and
GI bleeding. The common mode of action of these
compounds was described in 1971 by Sir John Vane, who
recognized that aspirin and NSAIDs inhibit production
of PGs (3). He proposed that the therapeutic effects and
the main side effects of these compounds result from
blocking formation of PGs.
The enzymes involved in the biosynthesis of
prostaglandins include the phospholipases that release
arachidonic acid from phospholipid membranes, partic-
ularly phospholipase A2 (PLA2). Arachidonate is metab-
olized to PG by the bifunctional enzyme cyclooxygenase
(COX or PGH synthase), after which stable PGs are
formed by a group of synthases. In general, the partic-
ular PG produced by a given cell type is determined by
the PG synthase present in that cell (4). The principal
mechanism of action for aspirin and NSAIDs is inhibi-
tion of the enzymatic activity of COX.
Until 1990, it was thought that the rate-limiting
step in prostanoid biosynthesis was the availability of
arachidonic acid substrate. However, Masferrer et al, in
the laboratory of Dr. Philip Needleman, made the
observation that COX protein in mice was increased by
exposure to bacterial endotoxin and, furthermore, that
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the levels of COX protein were decreased by glucocor-
ticoids (5). It was also shown that levels of COX protein
were increased in rats with experimental inflammatory
arthritis and in synovial tissues of patients with rheuma-
toid arthritis (RA) compared with those of patients with
osteoarthritis (OA) (6). It was proposed that different
pools of COX might be present, and encoded by differ-
entially regulated genes (5). This hypothesis was shown
to be correct when a gene product found to be induced
by either stimulation of 3T3 mouse fibroblasts with
phorbol ester or infection of chick embryo fibroblasts
with the oncogene v-src was identified as an isoform of
COX, now known as COX-2 (7,8). Masferrer and co-
workers further hypothesized that the presence of dif-
ferent COX enzymes could have functional conse-
quences, that is, one isoform could be responsible for the
PGs produced in pathologic situations whereas physio-
logic PGs might be the product of another COX isoform
(5). If this is indeed the case, then specific inhibition of
COX-2 might provide the therapeutic benefits associ-
ated with NSAIDs without the usual side effects.
Biology of COX-2
Molecular biology. After the gene for COX-2 was
cloned and characterized, comparisons with COX-1
could be made. The most striking difference between the
COX isoforms was at the level of basal expression and
regulation of the messenger RNA (mRNA) (9). The
promoter region of COX-1 has the characteristics of a
housekeeping gene, a gene that is continuously tran-
scribed and stably expressed, including the absence of
TATA and CAAT elements. COX-1 mRNA and protein
are expressed in most tissues under basal conditions as a
result of these molecular characteristics of the promoter
(10) (Figure 1). COX-1 levels are increased as some cell
types differentiate (11); however, mRNA and protein
levels do not vary greatly in response to external stimuli
in differentiated tissues. COX-1 is the only isoform
expressed in platelets, and is responsible for production
of PGs that maintain the integrity of normal gastric
mucosa (12). COX-1 is also available to increase PG
production acutely when an abrupt increase in arachid-
onate substrate occurs (13,14).
The COX-2 gene has the structure typical of
highly regulated gene products (9). The promoter region
has TATA and CAAT elements as well as binding sites
for transcription factors that act to increase gene tran-
scription immediately in response to external stimuli
(9,15). In addition, the 39-untranslated region encodes
multiple mRNA instability sequences that are usually
found in genes whose products are rapidly down-
regulated after induction (16–18). COX-2 has markedly
restricted expression under basal conditions, with the
highest levels found in the brain, vas deferens, and renal
cortex (2). As would be predicted, COX-2 expression is
highly induced by a number of cytokines, including
interleukin-1 (IL-1), tumor necrosis factor a, and other
stimuli associated with inflammation and growth (9,19).
It has been confirmed that COX-2 expression is inhib-
ited by glucocorticoids in all cells and tissues studied
to date (9).
There is considerable variability in the specific
transcription factors that mediate increased COX-2 ex-
pression depending on the cell type and species under
investigation. Several investigators have reported that
nuclear factor kB (NF-kB) is an important mediator of
COX-2 transcription in some human cells, including
synovial fibroblast-like cells (20,21), whereas others have
reported that NF-kB has no role in regulating COX-2
expression. Similar cell-type and species variability has
been noted for other transcription factors that are likely
to play a role in COX-2 regulation, including c/EBP and
c-jun (22). In addition to being highly regulated at the
transcriptional level, COX-2 expression is regulated
posttranscriptionally. IL-1 increases COX-2 mRNA
half-life in addition to increasing transcription (18). The
Figure 1. Expression of cyclooxygenase-1 (COX-1) and COX-2.
COX-1 expression is constitutive in most tissues. There are a few
situations in which COX-1 is modestly increased during cellular
differentiation. COX-2 exhibits restricted expression under basal con-
ditions, but can be markedly induced in response to stimulation by
cytokines, mitogens/growth factors, hormones, and many other patho-
logic and physiologic stimuli.
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mechanisms by which glucocorticoids inhibit COX-2
expression have not yet been completely elucidated, and
it is likely that transcriptional and posttranscriptional
mechanisms are involved (17,23). However, it seems
clear that antiinflammatory actions of glucocorticoids
are mediated in part through inhibition of prostanoid
biosynthesis by inhibiting the expression of COX-2.
Although the synthesis of PGs is regulated
acutely by activation of phospholipases and release of
arachidonate, the net level of prostanoid production is
determined by COX expression (24). Control of COX
isoform levels is critical since the enzyme is inactivated
during catalysis. Many agents that stimulate arachido-
nate release, such as cytokines and growth factors, also
stimulate transcription of COX-2, and full prostanoid
biosynthetic capacity is reached only when COX-2 is
induced (24).
Enzymatic activity. Despite differences in the
expression and regulation of COX-1 and COX-2, the
enzymatic activity of the isoforms is strikingly similar.
The crystal structure of both isoforms has been deter-
mined, and predictions regarding the interactions of
arachidonic acid substrates as well as inhibitors can be
made using this information. Both COX isoforms are
localized within the inner leaflet of the phospholipid
bilayer of the endoplasmic reticulum and nuclear enve-
lope (25,26). Localization of the COX isoforms may be
of importance since COX is one of a cascade of enzymes
that participates in PG production. Of note, cytosolic
PLA2, a leading candidate for the principal enzyme
generating arachidonic acid in response to external
stimuli, translocates to the nuclear envelope upon acti-
vation (27,28). The first reaction catalyzed by both COX
isoforms involves the oxidative cyclation of the central 5
carbon atoms of arachidonic acid, leading to the forma-
tion of PGG2. This reaction takes place in a hydrophobic
channel in the interior of both COX proteins that can be
accessed from within the phospholipid membrane. A
peroxidation reaction that results in the formation of
PGH2 occurs at a separate, but neighboring, cataly-
tic site (4).
Most of the amino acids that form the enzymatic
active site of the COX molecules are identical, with the
exception of the substitution of valine in COX-2 for
isoleucine in COX-1 at position 523. This substitution
allows formation of a side pocket in COX-2 that has
been shown to be critical in allowing the development of
pharmaceutical compounds that specifically inhibit
COX-2 (29). The interaction of arachidonate with
COX-1 and COX-2 may be different, as evidenced by
differing effects of amino acid substitutions for the
arginine 120 located at the mouth of the hydrophobic
channel in both enzymes. It is likely that an ionic bond
with arachidonate is formed by COX-1 while a hydrogen
bond is formed by COX-2, suggesting that the hydro-
phobic cyclooxygenase channel must contribute more
significantly to arachidonate binding to COX-2 (30).
Overall, COX-2 has a wider and somewhat more flexible
interior channel. One consequence of this property of
COX-2 is that the interaction of aspirin with COX-2
results in formation of unique fatty acids whose products
may have intrinsic antiinflammatory activity (31).
COX-2 in inflammation, pain, and fever. In
virtually all models studied, COX-2 expression increases
in response to inflammatory stimuli and other types of
tissue damage. Since NSAIDs are efficacious in the
treatment of arthritis and other forms of acute and
chronic inflammation, examination of the relative ex-
pression of COX-1 and COX-2 in these types of disor-
ders provides some insight into potential roles for the
isoforms and potential therapeutic benefits of specific
COX-2 inhibition.
Both COX-1 and COX-2 are expressed in syno-
vial tissues of patients with arthritis. COX-1 is localized
at the synovial lining layer, and there is no difference in
the level of expression in inflammatory versus nonin-
flammatory arthritides (32). COX-2 is localized to the
sublining layers, particularly the vascular endothelial
cells, infiltrating mononuclear inflammatory cells, and
fibroblast-like synoviocytes. Its expression is increased in
inflammatory forms of arthritis (32,33).
The role of PGs in inflammation and pain is both
local and central within the nervous system. In peripheral
tissues, PGs prolong proinflammatory actions of bradyki-
nin, histamine, nitric oxide, and other mediators. Centrally,
there is constitutive expression of COX-2 in the spinal
cord, which is up-regulated during inflammation (34).
Animal models of inflammation have been used to address
the relative roles of COX-1 and COX-2. These data
demonstrate that peripheral tissue PG production can be a
function of both COX-1 and COX-2 in different types of
models (35). Markedly increased COX-2 expression that
paralleled increased PG production has been seen in
animal models of inflammatory arthritis and in the rat
carrageenin- or lipopolysaccharide-stimulated air pouch
models. Pharmacologic compounds that specifically inhibit
COX-2 reversed inflammation in both of these models
(36,37). In the air pouch models, a specific inhibitor of
COX-1 had no effect on PGE2 production (35). However,
in a dermal Arthus reaction model, a specific inhibitor of
COX-1 decreased production of PGs while a specific
inhibitor of COX-2 had no effect (35).
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Findings in the carrageenin-induced footpad in-
flammation model were somewhat more complex. Both
COX-1– and COX-2–specific inhibition decreased PGE2
production in inflamed tissues. However, only the spe-
cific COX-2 inhibitor inhibited inflammation and hyper-
algesia. The antiinflammatory and analgesic activity of
specific COX-2 inhibition correlated with decreased
cerebrospinal fluid PG levels (35). Further studies dem-
onstrated that intrathecal administration of a specific
COX-2 inhibitor could block the initiation of thermal
hyperalgesia (38). These data suggest the possibility that
some antiinflammatory, as well as the analgesic, effects
of COX-2 inhibition may result from blocking of neuro-
genic inflammation. This possibility, however, runs
counter to the observation that inhibition of tissue PGE2
using a monoclonal antibody blocks inflammation
equally as well as NSAIDs (39). Nevertheless, COX-2 in
the central nervous system seems to play an important
role in the therapeutic efficacy of NSAIDs and specific
COX-2 inhibitors.
Fever occurs in response to inflammation and
induction of cytokines. PGs have long been known to
mediate the fever. COX-2 expression is induced in the
brain vasculature, with temporal correlation to the de-
velopment of fever (40). Moreover, mice with targeted
COX-2 gene disruption fail to develop fever in response
to inflammatory stimuli (41).
COX-2 in tissue repair. Induction of COX-2
represents an early response to tissue injury caused by a
number of stimuli in many different tissues, and is likely
to play a physiologic role in tissue repair. Of clinical
interest, COX-2 expression is increased in the GI tract,
similar to other tissues, in response to injury (42–45).
Patients with Helicobacter pylori–associated ulceration
have increased COX-2 expression in gastric mucosa.
After treatment of the infection, COX-2 levels are
decreased (43). The significance of COX-2 for produc-
ing protective prostanoids in these settings relative to
COX-1–mediated PG production is not clear, although
it has been shown that specific inhibition of COX-2
delays healing of gastric mucosal erosions and ulcers in
mice (46). Inhibition of COX-2, using either standard
NSAIDs or a specific inhibitor, has also been shown to
increase mucosal damage and mortality related to per-
foration in a rat model of colitis (42). These data
indicate that although COX-1 seems to be responsible
for cytoprotection of normal gastroduodenal mucosa
(37,47,48), further clinical evaluation is needed to deter-
mine what role COX-2 may play in the healing of
damaged GI mucosa.
COX-2 expression is increased in endothelial
cells and myocytes of infarcted myocardium. COX-2
staining is also seen in myocytes of myocardial fibrosis
associated with dilating cardiomyopathy (49). There is
an emerging concept that COX-2 induction in endothe-
lial cells may represent an important compensatory
mechanism to defend against vascular injury in general
and may also be cardioprotective (50). The observation
that some COX-2 knockout mice develop cardiac fibro-
sis supports this hypothesis (51). The fact that only
COX-1 is expressed in platelets and is responsible for
thromboxane A2 (TXA2) production during platelet
activation, while endothelial cells have the capacity to
express both COX-1 and COX-2, may have implications
regarding vascular physiology in patients treated with
specific COX-2 inhibitors.
The notion that induction of COX-2 is critical to
normal tissue repair is supported by observations in
patients with idiopathic pulmonary fibrosis (IPF). Cul-
tured lung fibroblasts from patients with IPF fail to
express COX-2 in response to stimulation with IL-1 (52).
This observation, taken together with data demonstrat-
ing that PGs influence the balance between collagen
deposition and matrix metalloproteinase production in
fibroblasts (53), indicates that failure to induce COX-2
normally may contribute to the development of fibro-
sis in IPF.
COX-2 in malignancy and angiogenesis. There is
very strong evidence suggesting that PGs play a role in
the progression of colon cancer. Animal models of
colon carcinogenesis, genetic and induced, indicate
significant inhibition by NSAID treatment (2). There
is a 40–50% decreased risk for colorectal cancer in
persons who take aspirin or NSAIDs regularly, and
NSAIDs cause regression of preexisting adenomas in
patients with familial adenomatous polyposis (2).
COX-2 expression is up-regulated in adenomas and
carcinomas of the colon in animals and humans.
Specific COX-2 inhibition, either by targeted knock-
out of the COX-2 gene or by pharmacologic means,
has been shown to effectively modulate colon carci-
nogenesis (2,54). Several mechanisms for this effect
have been proposed. Overexpression of COX-2 in rat
intestinal epithelial cells results in resistance to apo-
ptosis and several other phenotypic changes that
could lead to dysregulation of growth and normal cell
death (55). In addition, it has been suggested that
overexpression of COX-2 could promote production
of angiogenic factors (56). A role for COX-1 in colon
carcinogenesis has not been excluded, and there may
be mechanisms other than inhibition of COX by which
NSAIDs are cancer chemopreventative (2).
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COX-2 as a mediator of physiologic processes.
Although COX-2 was originally described as mediating
production of pathologic PGs, it is clear that COX-2 also
catalyzes formation of prostanoids that are important
for physiologic functions (Figure 1). Although use of
NSAIDs is known to prolong labor, the extent of COX-2
involvement in reproductive function was perhaps not
fully appreciated until it was shown that COX-2 knock-
out mice had impaired fertility (57). It is now evident
that COX-2 is rapidly and transiently induced by lutein-
izing hormone in preovulatory follicles and may be
responsible for the precise timing of ovulation (58,59).
In addition, there is a focal increase of COX-2 expres-
sion at the site of blastocyst attachment in the uterus
(60). COX-2 is highly expressed constitutively in the vas
deferens of the adult male rat. Expression appears to be
dependent on androgen since castration depletes
COX-2 and androgen replacement after castration re-
stores levels of COX-2 (61). It was recently reported that
COX-2 is expressed in the fetal lamb ductus arteriosus,
predominantly in endothelial cells, while COX-1 is ex-
pressed in endothelium and smooth muscle. Both con-
tributed to production of PGE2 by ductus tissue (62).
It has been known for many years that PGs are
potent regulators of bone metabolism. Mechanical
forces, hormones, cytokines, and growth factors increase
production of prostanoids in skeletal tissues. It has
recently been recognized that this is related, in large
part, to transcriptional regulation of COX-2 (63), al-
though COX-1 is also present in these tissues and the
relative roles of the isoforms have yet to be fully
elucidated (64). This is a potentially critical question if
prostanoids produced by different isoforms regulate
different aspects of bone remodeling. For example,
mechanical loading significantly increases the rate of
endocortical bone formation. Whereas indomethacin
only partially inhibited bone formation in this model, a
specific COX-2 inhibitor completely blocked bone for-
mation (65).
In pancreatic islets, COX-2 is the dominant iso-
form both under basal conditions and, as expected, after
stimulation by IL-1 (66). PGs were previously shown to
inhibit glucose-induced insulin secretion, but the impli-
cations of COX-2 expression in islet cells remain un-
certain (66).
Prostanoids are involved in multiple physiologic
processes in the lung, including regulation of pulmonary
vascular tone, regulation of capillary endothelial and
alveolar epithelial permeability, surfactant homeostasis,
and control of bronchial mucous secretion and transport
(67). COX-1 and COX-2 are expressed in different cells
and tissues of the lung. COX-2 is expressed under basal
conditions in macrophage- and mast cell–like cells in
proximity to bronchial epithelium. Expression of COX-2
is also observed in smooth muscle cells of muscular
arteries (67). The significance of distinct patterns of
expression of the COX isoforms in different cells of the
lung in regard to pulmonary physiology must be evalu-
ated further.
COX-2 expression is regulated developmentally
in the rat brain, with adult expression mostly in neurons
of the limbic system and cortex (68). Up-regulation of
COX-2 occurs in response to experimentally induced
seizures as well as normal neuronal activity. COX-2 is
hypothesized to play a role in development of Alzhei-
mer’s disease, although data are conflicting as to
whether COX-2 is actually increased or decreased in the
brain of patients with this disease (69–72).
The critical role of PGs in renal physiology is
demonstrated by the fact that alterations in renal func-
tion develop in some patients treated with NSAIDs.
Localization studies of the COX isoforms in rat kidney
have demonstrated distinct expression of COX-1 and
COX-2. COX-2 is expressed in the adult rat renal cortex
in a restricted subpopulation of cells localized to the
cortical thick ascending limb cells in the regions of the
macula densa and in medullary interstitial cells (73). The
macula densa is an important site of regulation of
glomerular blood flow and renin release. When rats
were subjected to sodium restriction, COX-2 localized to
the macula densa increased (73). It has been suggested
that PGs produced via the COX-2 pathway may stimu-
late renin release. Further studies are needed to clarify
whether COX-2 is similarly localized in the human
kidney, but preliminary studies have indicated that
COX-2 is present in the glomerular podocytes and the
vasculature (74,75).
Evidence that COX-2 plays a role in renal func-
tion in humans is provided by clinical trials demonstrat-
ing an excess of edema when high doses of specific
COX-2 inhibitors are given (76). Additionally, in healthy
elderly volunteers, specific COX-2 inhibitors decreased
renal prostacyclin production and led to a significant
transient decline in urinary sodium excretion (77,78).
Whereas the changes in sodium excretion were compa-
rable between specific COX-2 inhibitors and nonspecific
NSAIDs, only nonspecific NSAIDs reduced the glomer-
ular filtration rate in subjects with normal renal
function (78).
COX-2 plays a role in the development of the
rodent kidney, as demonstrated by the finding of severe
renal abnormalities in COX-2 knockout mice (14,51).
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Localization studies show that COX-2 expression is
subject to developmental control in the rat kidney, with
peak expression in the second and third postnatal weeks
and declining to adult levels by the third month (79).
PGs are regulators of platelet and endothelial cell
function and, as such, modulate the hemostatic/
thrombotic balance. COX-2 appears to play a role in the
production of endothelial PGI2. In vitro studies demon-
strate that COX-2 expression is up-regulated in endo-
thelial cells by laminar shear stress (80). Furthermore,
specific COX-2 inhibitors decrease systemic PGI2 pro-
duction in healthy volunteers (77,78). Clinical implica-
tions of these biologic observations are currently un-
known, and the possibilities are discussed below.
Specific COX-2 inhibition in clinical practice
Definition of specific COX-2 inhibition. Several
levels of data are available to determine whether a
compound is, in fact, a specific COX-2 inhibitor. First,
the compound should exhibit specificity in vitro. In vitro
specificity, however, is far from adequate and can only
be suggestive of specificity because of the large number
of variables in this type of assay (81). The most widely
accepted ex vivo measure of COX-2 specificity is the
whole blood assay. The assay is performed by measuring
both COX-1 and COX-2 activity in a single sample.
COX-1 activity is measured by determining thrombox-
ane B2, the breakdown product of platelet TBA2, during
whole blood clotting. COX-2 activity is measured by
determining PG production from stimulated monocytes
(12). Specific COX-2 inhibitors should not inhibit plate-
let aggregation over the entire range of doses and times
in which PG production from stimulated monocytes is
maximally inhibited (81). For the purpose of this discus-
sion, celecoxib and rofecoxib will be considered specific
COX-2 inhibitors (47,82).
Implicit in the designation of a compound as a
specific COX-2 inhibitor is the notion that there will be
fewer clinically meaningful GI effects, i.e., ulcer with
bleeding, perforation, or obstruction. As more is learned
about the normal physiology of COX-2, the clinical
definition of a specific inhibitor may change (Figure 2).
Nevertheless, from a clinical standpoint, there are two
key questions for evaluating the specific COX-2 inhibi-
tors in comparison with other NSAIDs: Are they equally
effective for arthritis and/or pain? Are there differences
in the side effect profiles?
Efficacy of specific COX-2 inhibitors in arthritis
and pain. Experience with both celecoxib and rofecoxib
suggests that their efficacy is equal to that of nonselec-
tive NSAIDs. In the first 2-week trial of celecoxib in OA,
celecoxib at doses of 100 mg and 200 mg twice daily was
superior to placebo at weeks 1 and 2 as measured by
visual analog scale for pain and by patient global assess-
ment (47). In RA, celecoxib at 200 mg and 400 mg twice
daily was superior to placebo at weeks 1, 2, and 4 for
patient global assessment and number of tender/painful
joints. Celecoxib at a dosage of 40 mg twice daily was
effective in OA at week 1, but was ineffective in RA (47).
The frequency of withdrawals due to inefficacy in the
RA trial was significantly lower for celecoxib at 200 mg
and 400 mg twice daily (4% and 6%, respectively) than
for placebo and celecoxib at 40 mg twice daily (18% and
17%, respectively) (47).
The efficacy of rofecoxib (50 mg and 500 mg) was
comparable with that of ibuprofen (400 mg) and supe-
rior to that of placebo in a dental pain model of
analgesic effect (82). Early studies in OA of the knee
demonstrated efficacy of rofecoxib compared with pla-
cebo at daily dosages of 25 mg and 125 mg for 6 weeks
(n 5 72–74 per group), with decreased pain and im-
proved function evident by 1 week and sustained over
the duration of the study (76). There were fewer with-
drawals because of lack of efficacy in the rofecoxib
groups, and there was no difference in the number of
adverse events among groups (76). There was, however,
an increased number of patients reporting lower extrem-
ity edema in the rofecoxib 125 mg group (6.8%, com-
pared with 0% in the placebo group).
In a 52-week trial of rofecoxib at 12.5 mg or 25
mg twice daily compared with diclofenac at 75 mg twice
Figure 2. Clinical effects of cyclooxygenase-2 (COX-2) inhibitors.
Specific COX-2 inhibitors share therapeutic effects and some side
effects with nonspecific COX inhibitors. The primary differences
between specific COX-2 inhibitors and nonspecific COX inhibitors are
the lack of antiplatelet activity and reduction of gastroduodenal
mucosal injury with specific COX-2 inhibitors. There may be distinct
roles for the different COX isoforms in renal physiology. As the
biology of the COX isoforms is clarified, clinical definitions of the
specific COX-2 inhibitors may change. GI 5 gastrointestinal; RBF 5
renal blood flow; GFR 5 glomerular filtration rate.
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daily in patients with OA of the knee or hip (n 5
257–268 per group), rofecoxib was comparable with
diclofenac for all efficacy outcome measures (83). Treat-
ment responses were seen in all treatment groups at the
first time point studied, and were sustained at a gener-
ally consistent level throughout the entire year of treat-
ment (83). Response was observed in a variety of
parameters, including stiffness, physical function, and
study joint tenderness, and occurred in both OA of the
knee and OA of the hip (83). There were no significant
differences in the rates of discontinuation due to in-
efficacy.
GI effects of specific COX-2 inhibitors. Simon et
al published the first results suggesting potential for
improved GI safety with celecoxib (47). A short-term
(61⁄2-day) study in healthy volunteers demonstrated
marked reduction of endoscopically evident ulcers and
erosions among patients treated with celecoxib com-
pared with those receiving naproxen (n 5 32 per group).
The incidence of ulcers .3 mm in the naproxen group
was 19%, whereas there were no ulcers in the placebo or
celecoxib groups. There was a 72% incidence of gastric
erosion or ulcer in the naproxen group, compared with
9–13% in the placebo and celecoxib groups. In the
published clinical experience for celecoxib in normal
volunteers and patients with OA and RA, the incidences
of nausea, dyspepsia, and abdominal pain were some-
what less than for a comparitor NSAID (naproxen).
However, there were no differences in the rates of
withdrawals from efficacy trials because of adverse
events (47).
Two large endoscopic studies of 24 weeks’ dura-
tion compared endoscopic outcomes of treatment with
rofecoxib at a dosage of 25 mg or 50 mg per day,
ibuprofen 800 mg 3 times daily, and placebo (n 5
340–373 per group [pooled data from both studies]).
The studies were performed in OA patients .50 years of
age. Patients with active erosive esophagitis or active
upper GI ulceration were excluded, but patients with an
earlier history of ulcer, perforation, or GI hemorrhage
(9–13%), gastroduodenal erosions (9–20%), or H pylori
infection (52–57%) at baseline were eligible, and their
numbers were comparable among groups. The fre-
quency of endoscopic ulcers $3 mm was significantly
lower in the rofecoxib groups compared with the ibupro-
fen group at 6, 12, and 24 weeks. At the 12-week time
point, the frequency of ulcers was 7.34% in the placebo
group, 4.69% in the lower-dose rofecoxib group, 8.07%
in the higher-dose rofecoxib group, and 28.47% in the
ibuprofen group (48). Placebo treatment was not con-
tinued to 24 weeks, but the marked difference between
rofecoxib and ibuprofen was maintained (ulcer fre-
quency at 24 weeks 9.74%, 13.53%, and 46.36% for
rofecoxib 25 mg, rofecoxib 50 mg, and ibuprofen 800 mg,
respectively). Earlier history of GI events and baseline
erosions were associated with increased ulcer incidence
in all groups, but H pylori status was not. There was no
evidence that rofecoxib additionally enhanced gastric
injury in these subgroups (48).
GI symptom side effect profiles in a 52-week
efficacy trial of rofecoxib 12.5 mg or 25 mg twice daily
compared with diclofenac 150 mg twice daily in OA were
similar between groups (n 5 257–268 per group) (83).
The incidence of nausea was 6.2%, 7.4%, and 9.7% in
the rofecoxib 12.5 mg, rofecoxib 25 mg, and diclofenac
groups, respectively, and the incidence of drug-related
combined GI adverse events was 18.1%, 20.6%, and
19.8%, respectively. The rate of discontinuation because
of GI adverse events was similar between groups (83).
These early clinical trials demonstrate that endo-
scopic ulceration is significantly reduced with specific
COX-2 inhibitors. However, too few patients have been
studied to be able to definitively demonstrate a reduc-
tion in clinically significant GI events. The endoscopic
data combined with lack of platelet effect give reason for
optimism that the specific COX-2 inhibitors will have an
improved GI safety profile compared with nonspecific
NSAIDs (48). It may be that specific inhibition of
COX-2 in the setting of an active or healing ulcer (both
specifically excluded in the endoscopic trials) will be
associated with risk of complications, although it seems
unlikely that the risk with a specific COX-2 inhibitor will
be equally as high as that with traditional NSAIDs.
Nevertheless, based on the information that COX-2 is
increased in ulcer margins, it is prudent to recommend
that ulcers be treated prior to initiation of therapy with
specific COX-2 inhibitors. It bears repeating that data
do not demonstrate a significant reduction of non–ulcer-
related GI symptoms (nausea, dyspepsia, abdominal
pain) with the specific COX-2 inhibitors.
Other clinical considerations. It is worth empha-
sizing that patients in need of cardiovascular or cerebro-
vascular protection should be treated with low-dose
aspirin when specific COX-2 inhibitors or nonspecific
NSAIDs are used (83). The incidence of cardiovascular
thromboembolic events was not different between spe-
cific COX-2 inhibitors and nonspecific NSAIDs in the
reported clinical trials (83), but inhibition of COX-1 has
a clear role in antiplatelet activity of aspirin and non-
specific NSAIDs (1). It would also seem prudent to
consider low-dose aspirin prophylaxis if a specific
COX-2 inhibitor is used in patients with risk factors for
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thromboses, especially those with connective tissue dis-
eases associated with vasculitis or vasculopathy, where
expression of COX-2 may be increased. The addition of
aspirin to a regimen of treatment with a specific COX-2
inhibitor will, of course, alter the overall risk for GI side
effects and other bleeding complications (84,85).
There is little information regarding clinical use
of specific COX-2 inhibitors in other situations in which
nonselective NSAIDs are not generally recommended,
particularly among patients with intrinsic or functional
renal insufficiency. High doses of rofecoxib (125 mg)
have been shown to be associated with an increased
incidence of lower extremity edema, although at the
dosages effective for OA (12.5 mg), the frequency of this
side effect is not different from that with nonselective
NSAIDs (76,83). In the large OA trials, there were no
meaningful changes in blood pressure or serum creati-
nine levels in any group (83). However, data from
normal volunteers suggest that specific COX-2 inhibi-
tors will have renal effects, i.e., on sodium excretion
(78). Until more data are available, patients with intrin-
sic or functional renal disease that would not be treated
with an NSAID should not be viewed as candidates for
therapy with a specific COX-2 inhibitor. Similarly, there
is no information regarding use of these agents in
patients with aspirin-induced asthma. Although these
drugs could be useful in the pre- and postoperative
period since they do not inhibit platelet function (47,82),
studies to demonstrate proper healing of wounds and
bone have not yet been reported. It should be noted that
celecoxib has a sulfonamide moiety, and caution should
be used if a patient has a known allergy to sulfa drugs.
Summary
In summary, COX-2 is a highly regulated gene
product that catalyzes the local production of PGs in
pathologic and physiologic situations (Figure 1). It is
clear that COX-2 is the isoform responsible for produc-
tion of the PGs that mediate inflammation, pain, and
fever. However, the role for COX-2 in normal physiol-
ogy is still being defined. Specific COX-2 inhibitors
represent a significant conceptual advance in therapy for
patients with arthritis. Although there is no expectation
of superior efficacy, clinical trials suggest that efficacy
will be comparable with that of nonselective NSAIDs.
Clinical trials demonstrate the potential for clinically
meaningful reductions in the incidence of the most
serious GI complications found with nonselective
NSAIDs, i.e., ulcer, perforation, and GI bleeding. Over
the next several years, treatment of large numbers of
patients with specific COX-2 inhibitors will help to
define the biology of COX-2. The magnitude of this
advance in the therapy of rheumatic diseases is yet to be
accurately determined, but the development of specific
COX-2 inhibitors may afford significant new treatment
options for many patients.
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